Has ACCORD BIOPHARMA INC had other FDA enforcement actions?

This is the only FDA action Argus HQ has on file for ACCORD BIOPHARMA INC as of 2026-07-14. Argus ingests new FDA enforcement records daily.

What kind of FDA record is this?

This is an Argus HQ record of a FDA Recall, tagged high severity by Argus HQ. FDA published the underlying record on 2026-07-08; Argus observed and indexed it on 2026-07-14.

Where can I verify this record directly with FDA?

The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

.hq

fda_recall · drug_recall · high

ACCORD BIOPHARMA INC — Class II recall: IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d…

Name: FDA Recall Record — ACCORD BIOPHARMA INC
Creator: Argus HQ
Published: 2026-07-08
License: https://argushq.ai/methodology

Event date: 2026-07-08 00:00:00Z
Observed: 2026-07-14 04:20:18Z
Source ID: D-0653-2026
Payload hash: b61e490f76bff1a17c4c49f7…

Summary

Lack of assurance of Sterility: Status: Ongoing.

Entities

ACCORD BIOPHARMA INC

View source record ↗

Frequently asked questions

Has ACCORD BIOPHARMA INC had other FDA enforcement actions?: This is the only FDA action Argus HQ has on file for ACCORD BIOPHARMA INC as of 2026-07-14. Argus ingests new FDA enforcement records daily.
What kind of FDA record is this?: This is an Argus HQ record of a FDA Recall, tagged high severity by Argus HQ. FDA published the underlying record on 2026-07-08; Argus observed and indexed it on 2026-07-14.
Where can I verify this record directly with FDA?: The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). ACCORD BIOPHARMA INC — Class II recall: IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d…. Digital Empire LLC. Retrieved from https://argushq.ai/events/fda-recall-accord-biopharma-inc-d-0653-2026

MLA

"ACCORD BIOPHARMA INC — Class II recall: IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d…." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/events/fda-recall-accord-biopharma-inc-d-0653-2026.

Chicago

Argus HQ Research. "ACCORD BIOPHARMA INC — Class II recall: IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d…." Digital Empire LLC. Accessed July 14, 2026. https://argushq.ai/events/fda-recall-accord-biopharma-inc-d-0653-2026.

BibTeX

@misc{argushq_argushq_ai_events_fda_recall_accord_biopharma_inc_d_0653_2026_2026,
  title = {ACCORD BIOPHARMA INC — Class II recall: IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d…},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire LLC},
  url = {https://argushq.ai/events/fda-recall-accord-biopharma-inc-d-0653-2026},
  note = {Accessed: July 14, 2026}
}

Informational only. Not legal, financial, or medical advice.